Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Parkin

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
AIDS Research and Human Retroviruses|August 15, 2009
Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsWei Huang, Jonathan Toma, Eric Stawiski, et al.
AIDS Research and Human Retroviruses|July 3, 2007
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and DJessica D Church, Sarah E Hudelson, Laura A Guay, et al.
The Lancet. HIV|September 16, 2023
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended useLawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
Journal of the International AIDS Society|October 24, 2018
Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg ConsensusHezhao Ji, Eric Enns, Chanson J Brumme, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry AnalysisMichael R Jordan, Martina Penazzato, Amandine Cournil, et al.
Journal of Virology|July 5, 2002
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitroMichael F Maguire, Rosario Guinea, Philip Griffin, et al.
Lancet (London, England)|March 23, 2005
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case reportMartin Markowitz, Hiroshi Mohri, Saurabh Mehandru, et al.
The Journal of Antimicrobial Chemotherapy|October 17, 2019
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistancePhilip L Tzou, Soo-Yon Rhee, Diane Descamps, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
AIDS Research and Human Retroviruses|August 15, 2009
Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsWei Huang, Jonathan Toma, Eric Stawiski, et al.
AIDS Research and Human Retroviruses|July 3, 2007
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and DJessica D Church, Sarah E Hudelson, Laura A Guay, et al.
The Lancet. HIV|September 16, 2023
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended useLawrence Mbuagbaw, Cristian Garcia, Bluma Brenner, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
Journal of the International AIDS Society|October 24, 2018
Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg ConsensusHezhao Ji, Eric Enns, Chanson J Brumme, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Human Immunodeficiency Virus (HIV) Drug Resistance in African Infants and Young Children Newly Diagnosed With HIV: A Multicountry AnalysisMichael R Jordan, Martina Penazzato, Amandine Cournil, et al.
Journal of Virology|July 5, 2002
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitroMichael F Maguire, Rosario Guinea, Philip Griffin, et al.
Lancet (London, England)|March 23, 2005
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case reportMartin Markowitz, Hiroshi Mohri, Saurabh Mehandru, et al.
The Journal of Antimicrobial Chemotherapy|October 17, 2019
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistancePhilip L Tzou, Soo-Yon Rhee, Diane Descamps, et al.
Pageof 7